-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$8.005233.33% Upside
Viracta Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Viracta Therapeutics, Inc.?
Viracta Therapeutics, Inc. has been rated by research analysts at RBC Capital in the past 90 days.